**Section: Contact Information**

First Name: Arin  
Last Name: Madenci  
Institution: Boston Children's Hospital / Dana-Farber Cancer Institute  
Address 1: 300 Longwood Avenue  
City: Boston  
State/Province/Region: MA  
Country: US  
Zip/Postal Code: 02115  
Phone Number: 617-355-4503  
Alternate Phone Number:  
Email Address: arin.madenci@childrens.harvard.edu

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed. : **Yes**  
The specific aims are clear and focused. : **Yes**  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title: Long-term Outcomes of Pelvic Sarcoma Based on Initial Treatment  
Planned research population (eligibility criteria):  
Five-year childhood cancer survivors (baseline cohort) diagnosed with sarcoma of the pelvis at age <21.  
Proposed specific aims:  
S.A. 1: To describe the difference in mortality among childhood pelvic sarcoma survivors treated with A) surgery alone vs. B) radiotherapy alone vs. C) surgery and radiotherapy.  
S.A. 2: To describe the difference in late effects* among childhood pelvic sarcoma survivors treated with A) surgery alone vs. B) radiotherapy alone vs. C) surgery and radiotherapy.  
*Late effects include functional outcomes (e.g. physical function, fertility, bowel/bladder), recurrence/second neoplasm, and CTCAE chronic health conditions.  
S.A. 3: To identify risk factors (in addition to surgery and radiotherapy) for the above primary (i.e. mortality) and secondary outcomes among childhood pelvic sarcoma survivors.  
Will the project require non-CCSS funding to complete? : **No**
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?

**Group: Does this project require contact of CCSS study subjects for:**
- Additional self-reported information: No
- Biological samples: No
- Medical record data: No

If yes to any of the above, please briefly describe.

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**
- Second Malignancy: Secondary
- Chronic Disease: Primary
- Psychology / Neuropsychology:
- Genetics:
- Cancer Control:
- Epidemiology / Biostatistics: Secondary

**Section: Outcomes or Correlative Factors**
- Late mortality: Primary
- Second Malignancy: Secondary, Correlative Factors

**Group: Health Behaviors**
- Tobacco: Correlative Factors
- Alcohol: Correlative Factors
- Physical activity: Secondary
- Medical screening:
- Other:

If other, please specify:

**Group: Psychosocial**
- Insurance:
- Marriage:
- Education:
- Employment:
- Other:

If other, please specify:

**Group: Medical Conditions**
- Hearing/Vision/Speech:
- Hormonal systems: Secondary
- Heart and vascular: Secondary
- Respiratory:
- Digestive: Secondary
- Surgical procedures: Secondary, Correlative Factors
Brain and nervous system:
Other:
If other, please specify:

**Group: Medications**
Describe medications:

**Group: Psychologic/Quality of Life**
BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

**Group: Other**
Pregnancy and offspring: **Secondary**
Family history:
Chronic conditions (CTCAE v3): **Secondary**
Health status: **Secondary**

**Group: Demographic**
Age: Correlative Factors
Race: Correlative Factors
Sex: Correlative Factors
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**
CCSS Statistical Center: **Yes**
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.

Will this project utilize CCSS biologic samples? : **No**
If yes, which of the following? :
If other, please explain:

**Section: Other General Comments**
Other General Comments: